BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26277642)

  • 1. Current indications for the surgical treatment of prolactinomas.
    Smith TR; Hulou MM; Huang KT; Gokoglu A; Cote DJ; Woodmansee WW; Laws ER
    J Clin Neurosci; 2015 Nov; 22(11):1785-91. PubMed ID: 26277642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.
    Zaidi HA; Cote DJ; Castlen JP; Burke WT; Liu YH; Smith TR; Laws ER
    World Neurosurg; 2017 Jan; 97():2-7. PubMed ID: 27671881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
    Giese S; Nasi-Kordhishti I; Honegger J
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
    Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
    J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery.
    Yi N; Ji L; Zhang Q; Zhang S; Liu X; Shou X; Lu B
    Endocrine; 2018 Oct; 62(1):76-82. PubMed ID: 29934876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.
    Han YL; Chen DM; Zhang C; Pan M; Yang XP; Wu YG
    Medicine (Baltimore); 2018 Nov; 97(45):e13198. PubMed ID: 30407358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).
    Berezin M; Shimon I; Hadani M
    J Endocrinol Invest; 1995 Jun; 18(6):436-41. PubMed ID: 7594238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.
    Amar AP; Couldwell WT; Chen JC; Weiss MH
    J Neurosurg; 2002 Aug; 97(2):307-14. PubMed ID: 12186458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transsphenoidal microsurgical results of female patients with prolactinomas.
    Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
    Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
    Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
    Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
    Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.